Solve Intelligence Awarded Technology Solution of the Year

Key insights

• Solve Intelligence beat five finalists, judged by IP counsel from Amgen, Pfizer, Eli Lilly, and twelve other leading organisations.
• Christian Berrios brings a Harvard virology PhD and six years of patent practice to Solve Intelligence's product team.
• Life sciences and chemistry are at the centre of the Solve Intelligence product roadmap.

The award was accepted on behalf of Solve Intelligence by Dr. Christian Berrios. Christian is a US patent agent, holds a PhD in Virology from Harvard University, and is a Legal & Product Engineer at Solve Intelligence.

The award category benchmarks the technology solutions for life sciences patent work, and Solve Intelligence was selected from a finalist list that included Anaqua, DLA Piper, Patently, PowerPatent, and Questel.

The 2026 judging panel is made up of some of the most experienced IP professionals working in life sciences today, including in-house counsel from Amgen, Pfizer, Eli Lilly, Takeda, Regeneron, Eisai, Ipsen, Sumitomo Pharma, Beam Therapeutics, BlueRock Therapeutics, and the Broad Institute, alongside partners from White & Case, Arnold & Porter, WilmerHale, Duane Morris, MBHB, and Day Pitney.

Christian Berrios and Solve Intelligence’s Life Sciences Team‍

Christian Berrios accepted the award on behalf of Solve Intelligence. Christian is a registered US patent agent with over six years of experience in the patent profession. He joined Solve from Sterne, Kessler, Goldstein & Fox, one of the largest IP boutique law firms in the United States, and previously practiced in the in-house IP team of Singular Genomics, a DNA sequencing company. Christian holds a PhD in Virology from Harvard University, where his doctoral research at the Dana-Farber Cancer Institute focused on viral oncology.

Christian is one of several people at Solve Intelligence with life sciences expertise contributing to product development. Others include US, UK and European qualified patent attorneys with life sciences patent experience, and engineers with PhDs in computational biology. This range of expertise lets Solve build features that life sciences teams actually need and iterate quickly on their feedback, rather than retrofitting a generic patent tool.

‍

Solve Intelligence’s Life Sciences & Chemistry Patent Offering

Solve supports life sciences and chemistry teams across the full patent lifecycle. The features below cover what's available today across drafting, prosecution, and litigation support for life sciences and chemistry teams.

Chemistry patent drafting

Draft patent applications with deep chemical structure integration. Import chemical structures from a range of file types (ChemDraw, MOL, SDF), or extract them directly from uploaded Excel, PDF or Word documents. 

Edit and manipulate structures in-editor using ChemDraw, reference them in AI chat and instructions, insert tables of compounds and structures directly into the document, and draft claims that reference genera with defined R-group substituents. Dedicated genus, species, and substituent workflows keep structure-heavy applications consistent from disclosure to claims.

Markush & genus structure building

Build genera without leaving the editor. Auto-generate genera from a set of species compounds by proposing common scaffolds and R-groups. Trigger AI-assisted genus regeneration to account for the addition of new species, and keep claim language and structure definitions synchronised throughout the application.

Sequence listing management

Draft patent applications including sequences and generate ST.26 files for direct filing. Import sequences from ST.26 XML, FASTA, raw text, Word, and Excel files. Detect and delete duplicate sequences, renumber sequences consistently across application text and disclosure documents, reference sequences in AI chat and instructions, and insert tables of sequences directly into the document. Identify CDRs and framework regions automatically using standard schemes such as Kabat, which are also added to the Sequence ID list.

Patent prosecution

Respond to office actions with AI-assisted analysis of rejections. Draft arguments addressing Examiner rejections of lack of novelty, inventive step, and written description support for Markush breadth, and manage continuing application strategy across chemistry portfolios.

Freedom-to-operate, invalidity & litigation

Build claim charts to analyse clearance positions or invalidity arguments, and to identify infringement, revenue, and licensing opportunities under applicable legal standards (U.S. § 271, doctrine of equivalents, and EPC Art. 69).

‍

Looking ahead

Life sciences and chemistry sit at the center of Solve Intelligence's product roadmap. We're building AI-augmented reasoning for the problems that matter to this community: complex Markush structures, sequence-based infringement analysis, and a growing list of capabilities beyond. 

By developing these features alongside some of the world's leading life sciences and chemistry practice groups, we're making sure Solve Intelligence rises to the demands of protecting truly innovative science.  

We are expanding our global presence with new offices in New York and Munich, and deepening our collaboration with customers through initiatives like our Customer Advisory Board. We are grateful to be recognised by the world's leading law firms as the top IP platform, and we remain committed to the practitioner insight that got us here. 

To learn more about Solve Intelligence, request a demo.

‍

Frequently asked questions

1. How does the platform handle chemical structures and Markush claims?

This is the single most common question we hear in life sciences conversations.

Why it matters. Chemistry patent drafting is dependent on the ability to handle genus compounds, R-groups, and Markush structures. Tools built primarily for mechanical or software patents simply don't translate to small-molecule work, and patent attorneys want to know whether AI can actually meet the complexity of the field.

Our answer. Solve includes a built-in ChemDraw license (no separate purchase required), extracts structures from Excel, Word, and PDF inputs, and generates genus compounds from species selections with automatic R-group mapping. The platform supports SMILES and SMARTS notation natively.

‍

2. Is our confidential compound and sequence data secure?

This concern surfaces consistently with pharma and biotech clients.

Why it matters. Pre-filing compound structures and biological sequences are among a company's most sensitive IP. 

Our answer. Solve operates under zero data retention agreements with all of its LLM providers (Anthropic, OpenAI, Google). Data is sandboxed at the project level, and the platform is SOC 2 Type 2, ISO 27001, and ISO 42001 certified, with EU and US server options available.

‍

3. Does it support biological sequences (ST.26, antibodies, CDRs)?

The large-molecule counterpart to the chemistry question.

‍Why it matters. Antibody and biologics patent drafting depends on accurate sequence handling, CDR extraction, and ST.26 compliance.

Our answer. Solve provides full ST.26 XML import and export, sequence extraction from Excel, Word, FASTA, and GenBank files, automatic SEQ ID numbering, CDR extraction with multiple numbering schemes, duplicate detection, and antibody-specific workflows.

‍